iCAD (NASDAQ:ICAD) Share Price Crosses Above 200-Day Moving Average – Time to Sell?

iCAD, Inc. (NASDAQ:ICAD) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.59 and traded as high as $1.97. iCAD shares last traded at $1.83, with a volume of 138,448 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com raised shares of iCAD from a “sell” rating to a “hold” rating in a research note on Thursday, November 21st.

iCAD Price Performance

The firm’s 50 day simple moving average is $1.82 and its two-hundred day simple moving average is $1.59. The firm has a market capitalization of $54.94 million, a P/E ratio of -15.92 and a beta of 1.40.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in iCAD stock. Perritt Capital Management Inc boosted its position in iCAD, Inc. (NASDAQ:ICAD) by 14.2% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 159,900 shares of the technology company’s stock after acquiring an additional 19,917 shares during the period. Perritt Capital Management Inc owned 0.60% of iCAD worth $208,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.